Black checkmark with a sparkle and a curved line underneath on a white background.
Company

iBio, Inc.

Ticker
IBIO
Sector
Industry
Report date
November 11, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments for iBio include preclinical data releases demonstrating potential muscle preservation effects of IBIO-610, leadership changes, capital raises, and licensing agreements advancing its antibody pipeline.

Recent developments:
  • iBio reported preclinical data showing potential for muscle preservation with its IBIO-610 antibody [N1].
  • The company named Molly Carr as Chief Medical Officer in August 2026 [N2].
  • IBIO-610 achieved near-complete Activin E inhibition in an obese primate study, supporting its therapeutic potential [N4].
  • iBio announced a $26 million private placement to support its development programs in January 2026 [N6].
  • Jones Trading initiated coverage of iBio with a buy recommendation in March 2026 [N5].
  • The company priced a $50 million public offering in August 2025 to advance its preclinical antibody programs [N8].
  • iBio entered a licensing agreement with AstralBio for an Activin E-targeting antibody addressing obesity and cardiometabolic diseases in April 2025 [S1].
  • The company reported a net loss for Q1 2027 ending September 30, 2026, with EPS of -$0.05 [S2].
Overview

iBio, Inc. operates in the biotechnology sector with a focus on developing antibody-based therapeutics. Its pipeline includes preclinical programs targeting muscle preservation and metabolic diseases, notably through antibodies such as IBIO-610 which targets Activin E. The company has entered licensing agreements, including one with AstralBio for an Activin E-targeting antibody. Financially, iBio reported a net loss for the quarter ended September 30, 2026, but maintains strong liquidity with substantial cash, short-term investments, and a high current ratio. The company has raised capital through private placements and public offerings to fund its research and development activities. Leadership changes include the appointment of Molly Carr as Chief Medical Officer in 2026. iBio's business model centers on advancing its preclinical pipeline and leveraging collaborations to develop novel therapeutics.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. iBio, Inc. is a biotechnology company focused on developing preclinical antibody programs targeting muscle preservation and metabolic diseases. The company has demonstrated near-complete Activin E inhibition in obese primate studies with its IBIO-610 antibody. As of September 30, 2026, iBio reported a net loss of $7.551 million and held $45.435 million in cash and equivalents plus $31.2 million in short-term investments, reflecting strong liquidity with a current ratio of 9.48. Recent corporate developments include a $26 million private placement and the appointment of a new Chief Medical Officer. The company continues to advance its research and development pipeline through collaborations and licensing agreements.

Scenarios for IBIO

Bull case model:

The company has demonstrated promising preclinical data for its IBIO-610 antibody, showing near-complete Activin E inhibition in obese primates, which supports its potential in muscle preservation and metabolic disease treatment. Strong liquidity and recent capital raises provide resources to advance its pipeline. Strategic licensing agreements and leadership appointments indicate organizational commitment to development. Positive analyst coverage and initiation of buy recommendations reflect market interest in its prospects.

Bear case model:

iBio operates at a preclinical stage with limited current revenue and reported net losses, reflecting the high-risk nature of biotechnology development. The success of its antibody programs is uncertain and dependent on future clinical trial outcomes and regulatory approvals. The company faces risks related to funding, competition, and execution of its development plans. Market volatility and the need for continued capital raises may impact financial stability. The specialized focus may limit diversification of risk.

Moat:

iBio's moat is primarily based on its proprietary antibody technology platform and exclusive licensing agreements, such as the one with AstralBio for Activin E-targeting antibodies. The company's focus on first-in-class therapeutics addressing muscle preservation and cardiometabolic diseases positions it in a specialized niche within biotechnology. However, as a preclinical-stage company with limited revenue, its competitive advantage depends on successful clinical development and intellectual property protection. The moat is thus contingent on scientific innovation and the ability to advance candidates through regulatory pathways.

Risks overview
Risks summary
The primary risk for iBio is the uncertainty inherent in clinical development and regulatory approval of its preclinical antibody programs, compounded by financial and execution risks.
Risks details:

• Clinical and Regulatory Risk: The success of iBio's antibody programs depends on positive clinical trial results and regulatory approvals, which are inherently uncertain and may delay or prevent commercialization.
• Financial Risk: The company has reported net losses and relies on capital raises to fund operations, exposing it to risks related to liquidity and dilution.
• Competitive Risk: iBio operates in a competitive biotechnology sector with other companies developing similar therapeutics, which may impact market share and pricing.
• Execution Risk: Advancing preclinical programs to clinical stages requires effective management and operational execution, with risks of delays or failures.

FINAL FORECAST FOR IBIO

Final take one line
iBio, Inc. is a preclinical-stage biotechnology company with strong liquidity and advancing antibody programs targeting muscle preservation and metabolic diseases, supported by recent capital raises and licensing agreements.
Final take 12 to 24 month view

Business trends: Advancement of preclinical antibody programs targeting muscle preservation and metabolic diseases, supported by licensing agreements and positive preclinical data.
Execution milestones: Progress in clinical development of IBIO-610, leadership appointments, capital raises, and collaborations to support pipeline advancement.
Key risks: Clinical and regulatory uncertainties, financial reliance on capital raises, competitive pressures, and execution challenges inherent in biotechnology development.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • iBio, Inc. is a biotechnology company engaged in developing preclinical antibody programs targeting muscle preservation and metabolic diseases.
  • The company has a licensing agreement with AstralBio for a first-in-class Activin E-targeting antibody addressing obesity and cardiometabolic diseases.
  • iBio's IBIO-610 antibody has demonstrated near-complete Activin E inhibition in an obese primate study, indicating potential for muscle preservation.
  • The company named Molly Carr as Chief Medical Officer in August 2026.
  • iBio announced a $26 million private placement in January 2026 and previously priced a $50 million public offering in August 2025 to advance its preclinical antibody programs.
  • The company reported a net loss of $7.551 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.05 per share.
  • As of September 30, 2026, iBio had $45.435 million in cash and equivalents and $31.2 million in short-term investments, totaling $76.635 million in liquid assets.
  • The company had current assets of $81.239 million and current liabilities of $8.574 million as of September 30, 2026, resulting in a current ratio of 9.48 and a cash ratio of 8.94, indicating strong liquidity.
  • Revenue reported was $50,000 for the quarter ended March 31, 2024, indicating limited current revenue generation.
  • iBio has ongoing research and development activities focused on myostatin and Activin E antibodies, with corporate progress reported following its Nasdaq listing.
  • The company has executed agreements to exercise existing warrants for gross proceeds of $6.2 million.
  • Multiple equity incentive plans and stock option arrangements are in place as disclosed in SEC filings.
  • Recent news coverage includes initiation of coverage by Jones Trading with a buy recommendation and positive preclinical data releases.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-08-28 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-10-13 | www.nasdaq.com | IBio Reprots Preclinical Data Showing Potential For Muscle Preservation With IBIO-610 | https://www.nasdaq.com/articles/ibio-reprots-preclinical-data-showing-potential-muscle-preservation-ibio-610
  • N2 | 2026-08-04 | www.nasdaq.com | IBio Names Molly Carr As Chief Medical Officer | https://www.nasdaq.com/articles/ibio-names-molly-carr-chief-medical-officer
  • N3 | 2026-07-02 | www.nasdaq.com | Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal | https://www.nasdaq.com/articles/weekly-buzz-vrtx-aptx-gain-fda-nod-uncy-disappoints-ipsen-opens-wallet-vtgn-misses-goal
  • N4 | 2026-07-01 | www.nasdaq.com | IBio's IBIO-610 Achieves Near-Complete Activin E Inhibition In Obese Primate Study | https://www.nasdaq.com/articles/ibios-ibio-610-achieves-near-complete-activin-e-inhibition-obese-primate-study
  • N5 | 2026-03-04 | www.nasdaq.com | Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation | https://www.nasdaq.com/articles/jones-trading-initiates-coverage-ibio-ibio-buy-recommendation
  • N6 | 2026-01-09 | www.globenewswire.com | iBio Announces $26 Million Private Placement | https://www.globenewswire.com/news-release/2026/01/09/3216001/0/en/iBio-Announces-26-Million-Private-Placement.html
  • N7 | 2025-11-12 | www.nasdaq.com | iBio, Inc. (IBIO) Reports Q1 Loss | https://www.nasdaq.com/articles/ibio-inc-ibio-reports-q1-loss
  • N8 | 2025-08-20 | www.nasdaq.com | IBio Prices $50 Mln Public Offering To Advance Preclinical Antibody Programs | https://www.nasdaq.com/articles/ibio-prices-50-mln-public-offering-advance-preclinical-antibody-programs
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine